OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today ...
During Q2, OpGen's (NASDAQ: OPGN) reported sales totaled $1.19 million. Despite a 63.17% in earnings, the company posted a loss of $6.52 million. OpGen collected $616.93 thousand in revenue during Q1, ...
Tuesday, OpGen Inc (NASDAQ:OPGN) shares are trading higher after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E ...
Shareholder proxy vote achieves quorum with 99% support for the transaction Final step in OpGen / Curetis business combination achieved pending results of Special Meeting GAITHERSBURG, Md., March 24, ...
The OpGen Gene Panel product tests for causes of antimicrobial and antibiotic resistance in hospital patients. The FDA approval, CEO Oliver Schacht said, will help it move away from research and ...
GAITHERSBURG, Md., Dec. 18, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that it has provided the final report for completion of the contract from the Centers for Disease ...
OpGen ( (OPGN)) has provided an announcement. OpGen, Inc. appoints Mohd Azham Azudin as COO and Gillian Tan Rou Yee as Company Secretary, bringing extensive experience in private equity and corporate ...
Total revenue for 2022 was approximately $2.6 million Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million Conference call to be held March 29, 2023 at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results